Equity Profile

TYRA

Tyra Biosciences, Inc.

Health CareBiotechnology$1.5B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will help gauge how well Tyra is managing its costs relative to its revenues.

N/A

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal positive traction in Tyra's product development and market acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the health care sector, Tyra aims to address unmet medical needs through its research and development efforts, which could significantly impact patient outcomes and the broader healthcare landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, slightly missing estimates. The stock reacted positively, gaining 3.79% the following day, indicating some investor optimism despite the loss.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to managing operational costs effectively.
Plans to enhance investor communication regarding product development timelines.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of Tyra's earnings report, particularly given the recent stock price movement following earnings misses. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If Tyra can demonstrate progress in its clinical trials and manage costs effectively, it could lead to a positive surprise in EPS and revenue, driving the stock higher.

Bear Case

Conversely, if the company fails to provide clear updates on its clinical trials or shows continued losses without a clear path to profitability, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Tyra's key clinical trials?

Updates on clinical trials will be crucial for understanding the potential success of Tyra's therapies and their impact on future revenues.

How is Tyra managing its operational costs in light of ongoing losses?

Investors will be keen to hear about cost management strategies, as they are essential for moving towards profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Tyra's clinical trial updates, which could reveal more promising results than anticipated.

Supporting Evidence

The options market is indicating a larger move than historical averages, suggesting that traders expect significant news.

Tyra's recent stock performance indicates some investor optimism despite previous earnings misses.

Key Risk

If clinical trial results show unexpected positive outcomes, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on Tyra's ability to navigate its clinical development and financial management amidst ongoing challenges.

Bull Confirmed If

A positive update on clinical trial results could lead to a significant upward revision in growth expectations.

Bear Confirmed If

Failure to provide clarity on clinical trial progress or continued operational losses could lead to a downward reassessment of the stock.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect a volatile reaction to the earnings announcement.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests the stock could rise by about 0.18% on the day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors digest the information.

Miss

If Tyra misses expectations, history suggests an average decline of around 0.10%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for key clinical trials.
2Details on cost management strategies and operational efficiency.
3Insights into potential partnerships or collaborations.
4Comments on market competition and Tyra's positioning.
5Future guidance on revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will help gauge how well Tyra is managing its costs relative to its revenues.

N/A

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal positive traction in Tyra's product development and market acceptance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, slightly missing estimates. The stock reacted positively, gaining 3.79% the following day, indicating some investor optimism despite the loss.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to managing operational costs effectively.
Plans to enhance investor communication regarding product development timelines.

Expectations

Wall Street Expectations

Bull Case

If Tyra can demonstrate progress in its clinical trials and manage costs effectively, it could lead to a positive surprise in EPS and revenue, driving the stock higher.

Bear Case

Conversely, if the company fails to provide clear updates on its clinical trials or shows continued losses without a clear path to profitability, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of Tyra's key clinical trials?

Updates on clinical trials will be crucial for understanding the potential success of Tyra's therapies and their impact on future revenues.

How is Tyra managing its operational costs in light of ongoing losses?

Investors will be keen to hear about cost management strategies, as they are essential for moving towards profitability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Tyra's clinical trial updates, which could reveal more promising results than anticipated.

Supporting Evidence

The options market is indicating a larger move than historical averages, suggesting that traders expect significant news.

Tyra's recent stock performance indicates some investor optimism despite previous earnings misses.

Key Risk

If clinical trial results show unexpected positive outcomes, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter, the focus is on Tyra's ability to navigate its clinical development and financial management amidst ongoing challenges.

Bull Confirmed If

A positive update on clinical trial results could lead to a significant upward revision in growth expectations.

Bear Confirmed If

Failure to provide clarity on clinical trial progress or continued operational losses could lead to a downward reassessment of the stock.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect a volatile reaction to the earnings announcement.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests the stock could rise by about 0.18% on the day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may experience muted movement as investors digest the information.

Miss

If Tyra misses expectations, history suggests an average decline of around 0.10%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for key clinical trials.
2Details on cost management strategies and operational efficiency.
3Insights into potential partnerships or collaborations.
4Comments on market competition and Tyra's positioning.
5Future guidance on revenue expectations.